TTGTAGAAAGTGTGGTGCCAAA.
Negative PCR controls included omission of reverse transcriptase or omission of cDNA. Products were confirmed by highstringency Southern blotting with sequencespecific cDNA probes (data not shown).
Primary Antibodies. Immune serum or affinitypurified antibodies included: AQP1 (CHIP serum or LL266AP) (1); AQP2 (LL127 serum or LL127AP) (6, 19 ); AQP3 (LL178AP) (20) ; AQP4 (LL182 serum or LL182AP) (21); AQP5 (22, 23) . Affinitypurified polyclonal antibodies were also raised against the Cterminal region (amino acids 248-267) of rat and mouse AQP1 (RA3391/2353AP) and the C terminal region (amino acid 261-285) of rat AQP3 (RA3040/1592AP).
Membrane Fractionation and Immunoblotting. Tissues were homogenized for 20-30 sec and centrifuged at 4,000 × g for 15 min at 4°C. The resulting supernatant was centrifuged at 200,000 × g for 1 h to produce a pellet containing plasma membranes and intracellular vesicles.
Samples (2% SDS) were run on SDS12% polyacrylamide Laemmli minigels, transferred to nitrocellulose membranes, incubated overnight with rat primary antibodies, and visualized with horseradish peroxidaseconjugated secondary antibody (P0448, DAKO, Glostrup, Denmark) by enhanced chemiluminiscence (Amersham Pharmacia) (6).
Immunohistochemistry. Experimental animals were fixed by cardiac perfusion with 3% paraformaldehyde in 0.1 M cacodylate buffer, and tissues were extracted for paraffin embedding and sectioning. Paraffin sections (2 μm) were incubated overnight at 4°C with primary antibodies and visualized with horseradish peroxidaseconjugated secondary antibody (above). Punch biopsies of human tissues were incubated in 25 units/ml dispase (Roche Molecular Biomedicals, Hvidovre, Denmark) overnight on ice. The epidermis including intact sweat glands was gently removed from the dermis and fixed in neutral buffered formalin, rinsed, and kept in PBS with sodium azide. For staining, tissues were blocked in PB buffer (PBS, 0.3% Triton, 1% skimmed milk powder) and incubated overnight with human AQP5
antibody. Labeling was visualized with Alexa Fluor488 (Molecular Probes). Confocal microscopy used a Leica TCR2 (Leica, Deerfield, IL).
Immunoelectron Microscopy. Ultrathin Lowicryl HM20 sections (40-80 nm) were incubated overnight at 4°C with rat antiAQP5 antibodies (11, 22, 23) and visualized with goat antirabbit IgG conjugated to 10nm colloidal gold particles at 1:50 (GAR.EM10, BioCell Research Laboratories, Cardiff, U.K.). Sections stained with uranyl acetate and lead citrate were examined with a Philips CM100 or Philips 208 electron microscope (Philips, Eindhoven, The Netherlands).
In Vivo Sweat Response. Determination of pilocarpineinduced sweating was quantitated by a slightly modified standard method (24) , in which secreted amylase was detected by its reaction with iodine and starch. Adult AQP5null (−/−) mice, heterozygous (+/−), and wild type (+/+) were anesthetized (0.66 ml ketamine/0.22 ml xylazine in 2.5 ml isotonic NaCl; dose 0.625 ml per 100 g body weight). Right hind paws were painted with 3.5% iodine in ethanol and coated with 10% starch solution in mineral oil. Pilocarpine (50 μg) was injected s.c. into the paws, and digital photos taken every 15 sec for up to 5 min. Black spots were counted 2 min after pilocarpine injection.
Results are indicated as fraction of controls (wild type).
RESULTS
Detection of AQP5 mRNA by RT-PCR and Immunoblotting. RTPCR was performed on total RNA from rat paws ( Fig. 1 ) by using specific primers. Rat kidneys and lungs were positive controls. Consistent with evidence that AQP1 is present in capillary endothelia (3, 25) and AQP3 in the basal layer of the skin epithelium (26), AQP1 and AQP3 primers produced bands in samples from rat paws and kidneys.
AQP5 primers also produced a band in rat paws, identifying a previously unrecognized site for AQP5 expression. AQP2 and AQP4 primers failed to amplify mRNA from rat paws, but bands were produced from positive controls. Thus, AQP1, AQP3, and AQP5 mRNA were all detected in rat paws. Immunoblots prepared from rat paws were reacted with specific antibodies to AQP1-5. Membrane samples prepared from rat kidney inner medulla and lung were positive controls. AntiAQP1 specifically reacted with 29kDa (nonglycosylated) and 35 to 40kDa (glycosylated) forms of AQP1 in rat paws and kidney ( Fig. 2A) . AntiAQP3 antibodies specifically reacted with 27kDa (nonglycosylated) and 33 to 40kDa (glycosylated) forms of AQP3 in rat skin and kidney (Fig. 2B) . AntiAQP5 specifically reacted with a 27kDa band in rat paws and lung (Fig. 2C ). AntiAQP2 and antiAQP4 failed to react with samples prepared from rat paws (not shown). Thus, the expression of AQP1, AQP3, and AQP5 were confirmed in rat paws. Immunohistochemistry and Immunoelectron Microscopy. Cellular and subcellular localization of AQP1-5 were defined by immunoperoxidase labeling of 2μm paraffin sections from rat paws (Fig. 3 ) and mouse paws (Fig. 4) . The antiAQP1 labeling was confined to capillary endothelial cells in rat paws (Fig. 3A) , with no labeling of sweat glands or skin epithelium (Fig. 3F) . As expected (26) , basal levels in skin epithelium exhibited abundant antiAQP3 labeling (Fig. 3C ), but antiAQP3 labeling was not observed in sweat glands (Fig. 3H) .
Moreover, antiAQP2 and antiAQP4 immunolabeling were not observed in skin (Figs. 3 B and D) or in rat sweat glands (Figs. 3 G and   I ). AntiAQP5 did not label the skin epithelium (Fig. 3E) . Identical antiAQP1-5 labeling patterns were observed in mouse paws (not shown). Immunohistochemical staining revealed strong antiAQP5 labeling of both apical and basolateral plasma membrane domains of the secretory parts of mouse sweat glands (Fig. 4 A and B) . The same pattern was found in rat sweat glands (not shown). The apical membranes of proximal excretory ducts of sweat gland were also prominently labeled by antiAQP5 (Fig. 4C) , whereas distal excretory ducts were not labeled (Fig. 4D) . Sections of paw from AQP5null (−/−) mice failed to react with the antiAQP5 (Fig. 4E) , establishing the specificity of the labeling pattern. Also strong antiAQP5 labeling was seen in the apical plasma membrane domains of human sweat glands (Fig. 4F) . No apparent changes occurred in the distribution or number of sweat gland profiles in the wildtype and AQP5 null mice.
The subcellular localization of AQP5 in apical and basolateral plasma membranes of secretory cells in sweat glands was established by immunogold electron microscopy. Abundant antiAQP5 labeling of apical plasma membranes was observed in secretory parts of mouse sweat glands (Fig. 5 A and B) . Distinct labeling was also observed in basolateral plasma membranes (Fig. 5C) , consistent with the immunohistochemical findings. Almost no intracellular labeling occurred. Pilocarpine-Induced Sweat Response. Sections of rat and mouse paws in wildtype (+/+) and AQP5null (−/−) mice revealed no apparent differences in the number or morphological appearance of sweat glands (Fig. 4) . The ability of AQP5null (−/−) mice to secrete sweat was evaluated by painting hindpaws with iodine and starch solution, a standard method for detecting amylase, which causes the appearance of black spots over functional glands. Prior to pilocarpine injection (50 μg), few glands were observed (Fig. 6A) , whereas after 2 min, wildtype (+/+) mice had a higher number of visibly functional glands (arrows, Fig. 6B ) than did AQP5null (−/−) mice (arrowheads, Fig. 6D) . Quantification of functional glands from six wildtype (+/+) and seven AQP5null (−/−) mice showed a consistently lower number of active glands (23 ± 7%) in the AQP5null (−/−) mice when compared with normalized values for wild types (100 ± 24%; Fig. 6E ). Heterozygous mice (n = 3) showed a response not significantly different from wild type (data not shown). 
DISCUSSION
In this study, we demonstrate AQP5 expression in sweat glands by RTPCR, immunoblotting, and immunocytochemistry of rat and mouse paws. Abundant AQP5 immunolabeling was observed in secretory cells and in the excretory duct of sweat glands. Immunoelectron microscopy demonstrated that AQP5 labeling is predominantly associated with apical and basolateral plasma membranes of secretory cells of mouse sweat glands with only minor labeling of intracellular structures. Pilocarpineinduced sweat responses in AQP5null (−/−) mice were significantly reduced when compared with wildtype (+/+) and heterozygous (+/−) mice. These studies establish an essential role for AQP5 in sweat production that may be of importance for understanding thermoregulation and the pathophysiology of hyperhidrosis or hypohidrosis.
The localization of AQP5 in sweat glands and its possible role in sweat secretion had not previously been established. AQP1 is present in the microvasculature (3), and fluid secretion requires substantial fluxes of water from plasma to interstitium. AQP1 has a similar distribution in the vascular endothelial cells of rat exocrine pancreas as well as submandibular salivary glands (27) where it presumably serves a similar function. AQP3 is present at the basal levels of skin epidermis (26) . Several rat exocrine glands, including lacrimal glands (28, 29) , subepithelial glands of the upper airways (8) , and submandibular and parotid salivary glands (8) contain AQP5 in the apical membranes of acinar cells (30) . In this study, we showed that AQP5 is abundant in apical membranes and is also present in basolateral membranes of sweat glands in rat and mouse paws.
The sympathetic innervation of sweat glands elicits sweat secretion in rodents. It is not known, however, which steps are regulated by acetylcholine or catecholamines. Postganglionic fibers in sweat glands release acetylcholine, and catecholamines have been shown to act directly on gland cells to trigger their final differentiation for acquisition of secretory responsiveness (31) . Muscarinic agonists, like pilocarpine, mimic the ability of nerve stimulation to induce sweating (32, 33) , and sweating is blocked by muscarinic antagonists (34) .
Previous studies have suggested that multiple steps are involved in the coupling of muscarinic receptor stimulation to sweat secretion (32, 35) . Similar to sweat glands, rat salivary glands have abundant apical AQP5 in serous gland cells where autonomic nerve systems are innervated (8) . In parotid glands, stimulation of muscarinic receptors generates inositol 1,4,5trisphosphate and diacylglycerol via phospholipase C activation and increased phosphoinositide turnover. Generation of inositol 1,4,5trisphosphate leads to the increase in the intracellular calcium levels (36, 37) resulting in the rapid secretion of saliva (38) . This outcome may (39) possibly require translocation of AQP5 water channel proteins to the apical plasma membrane or other forms of activation (36, 40) . Consistent with this requirement, AQP5null (−/−) mice exhibit marked reduction in pilocarpinestimulated secretion of saliva (9) .
Our studies demonstrate the presence of AQP5 in sweat glands and a marked reduction in pilocarpineinduced sweat response in AQP5 deficient mice, thus raising the possibility that dysregulation of AQP5 may be important in several clinical disorders. Thus, dysregulation of AQP5 in sweat glands may contribute to the pathogenesis of hypohidrosis observed in patients with Sjögren's syndrome in whom markedly decreased sweating was evident in response to methacholine stimulation (14, 15) . In contrast, hyperhidrosis is a chronic idiopathic disorder of excessive sweating which may affect the palms, axillae, soles of the feet, and the face. It may be complicated by skin maceration as well as secondary microbial infections, and all the treatment modalities are associated with several complications (41) .
Our data suggest a key role of AQP5 in sweat production and raise the possibility that AQP5 inhibition may provide a new therapeutic option for reducing excessive sweating in this clinical disorder.
